A Randomized, Double Blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma who have Failed or are Intolerant to Sorafenib: The BRISK PS Study
ID Number 08-1469
Principal Investigator(s)Josep Llovet
Department(s) or Division(s)
Liver Diseases
Description
The purpose of this study is to determine if patients who have liver cancer and who have already received the drug sorafenib live longer when given the investigational drug brivanib alaninate (also known as brivanib) compared to those patients who receive placebo (a tablet that looks like brivanib, but has no active medicine in it). Additional purposes of the study are to determine if brivanib will help slow down the growth of the cancer, to test the safety of brivanib, and to evaluate the effect of brivanib on certain blood tests or tumor tissue (called biomarkers).
Contact Information
Hope Cassano
(212) 241-8903
hope.cassano@mssm.edu
Recruiting Patients: Yes